# **S1 Supporting Information**

Deuterium isotope effects in drug pharmacokinetics II: Substrate-dependence of the reaction mechanism influences outcome for cytochrome P450 cleared drugs

Hao Sun,\* David W. Piotrowski\*, Suvi T. M. Orr, Joseph S. Warmus, Angela C. Wolford, Stephen B. Coffey, Kentaro Futatsugi, Yinsheng Zhang and Alfin D. N. Vaz\*

Medicine Design, Pfizer Global Research and Development, Groton, Connecticut, United States of America

### **General Experimental Details**

All chemicals, reagents and solvents were purchased from commercial sources when available and used without purification. Proton (<sup>1</sup>H NMR) and carbon (<sup>13</sup>C NMR) nuclear magnetic spectroscopy were recorded with Varian or Bruker spectrometers. Chemical shifts are expressed in parts per million ( $\delta$ ) relative to deuterated solvent as an internal standard. The peak shapes are denoted as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet. Due to differences in solvents used in sample preparation and, in some cases amount of water present, not all exchangeable protons were observable. Mass spectrometry (MS) was performed via atmospheric chemical ionization (APCI) or electron scatter (ES) ionization sources. High resolution mass spectrometry was performed at NovaBioAssays (Woburn, MA) on Waters UPLC with TUV and Thermo Q Exactive MS instruments. Liquid mass spectrometry (LCMS) was performed on Agilent 1100 Series. Silica gel chromatography was performed using a medium pressure Biotage or ISCO Combiflash system, and Whatman pre-coated silica gel plates (250 µm) were used for analytical TLC. The synthesis of compounds 1a,<sup>1</sup> 2a,<sup>2</sup> and associated intermediates, **S2-S8** and **S11-S15**,<sup>1</sup> have been reported previously. Compounds **S1** (Bocpiperidin-4-one) and **S9** (4-trifluoromethoxyhydrocinnamic acid) were purchased from commercial sources as used as received.

## **Experimental procedures for compounds (1a-1f)**

Fig A.



To a solution of Boc-piperidin-4-one **S1** (500 g, 2.51 mol) in toluene (2 L) was added morpholine (250 g, 2.76 mol) and the flask was equipped with a Dean-Stark trap and the mixture was stirred under reflux for 18 h. The mixture was cooled to room temperature, and the solvent was removed under reduced pressure to give enamine **S2** (~720 g) as a yellow liquid. This material was used without further purification.

To a solution of enamine **S2** (~720 g) and triethylamine (327 g, 3.23 mol) in dichloromethane (2 L) was added ethyl oxalyl chloride (405 g, 2.96 mol) dropwise at 0 °C, the mixture was allowed to warm to room temperature while stirring for 18 h. The mixture was filtered and the filtrate was

concentrated under reduced pressure to give compound S3 (~250 g) as a yellow solid. This material was used without further purification.

To a solution of compound S3 (~1100 g, ~3 mol) in ethanol (4 L) was added S-methylthiourea (562 g, 3 mol) and triethylamine (1200 g, 11.9 mol) and the mixture was stirred under reflux for 18 h. The mixture was cooled to room temperature and filtered to give a yellow solid that was washed with dichloromethane (2 L). The filtrate was concentrated under reduced pressure to give compound S4 (~250 g) as a yellow solid. This material was used without further purification.

To a solution of compound **S4** (~120 g, 340 mmol) in methanol (3 L) was added a solution of 7 N ammonia in methanol (500 mL, 3500 mmol), and the mixture was stirred in a sealed bottle at 40 °C for 18 h. The mixture was cooled to room temperature and the solvent was removed under reduced pressure to give compound **S5** (~110 g) as a white solid. This material was used without further purification.

To a solution of compound **S5** (~108 g, ~333 mmol) in dichloromethane (2 L) was added mchloroperbenzoic acid (145 g, 767 mmol) in portions at 0 °C, and the mixture was allowed to warm to room temperature while stirring for 2 h. The reaction mixture was poured into a separatory funnel and washed with sat. aq. Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (2 x 300 mL), sat. aq. K<sub>2</sub>CO<sub>3</sub> (2 x 300 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated under reduced pressure to give compound **S6** (~118 g) as a white solid. This material was used without further purification.

To a solution of compound **S6** (~40 g, ~112 mmol) in THF (1.5 L) was added ethylamine (68 g, 1500 mol), and the mixture was stirred at 80 °C for 18 h. The solvent was removed under reduced pressure and the residue was crystallized from THF and ethyl acetate to give compound **S7** (22 g, 61%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  7.75 (br s, 1 H), 5.56 (br s, 1 H),

5.06 (br s, 1 H), 4.95-4.91 (m, 2 H), 3.72-3.67 (m, 2 H), 3.47-3.40 (m, 2 H), 2.84-2.82 (m, 2 H), 1.48 (s, 9 H), 1.27-1.19 (m, 3 H).

To a solution of compound **S7** (140 g, 436 mmol) in dichloromethane (400 mL) was added 4.0 M HCl in dioxane (1.5 L) dropwise at 0 °C, and the mixture was stirred at room temperature for 6 h. The mixture was filtered to give a solid that was further dried in a vacuum oven to give compound **S8** (122 g, 96%) as a white solid. <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz)  $\delta$  4.47 (s, 2 H), 3.47 (t, *J* = 6.8 Hz, 2 H), 3.35 (q, *J* = 7.2 Hz, 2 H), 3.05 (t, *J* = 6.8 Hz, 2 H), 1.09 (t, *J* = 7.2 Hz, 3 H); m/z = 222.1 (M+H)<sup>+</sup>.

Fig B.



To a solution of the amine **S8**-HCl salt (10.0 g, 34 mmol) in dichloromethane (250 mL) were added 4-trifluoromethoxyhydrocinnamic acid (**S9**) (8.9 g, 38 mmol), triethylamine (12 mL, 86 mmol), DMAP (5.2 g, 41 mmol), and EDCI (9.7 g, 48 mmol). The resulting mixture was stirred at room temperature for 18 h. The reaction mixture was diluted with ethyl acetate (300 mL) and 1 M aqueous HCl solution (300 mL) was added. The layers were separated and the organic layer was washed with 1N NaOH (300 mL), brine (300 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated under reduced pressure to give a clear oil. The crude material was purified by ISCO Combiflash system eluting with heptanes/acetone gradient to give 13.2 g of compound **1a** as clear oil that solidified upon standing. This material was recrystallized from acetonitrile to give 8.25 g (56%) of **1a**<sup>1</sup> as a white solid. mp 132-133 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  9.70 (br s, 1H), 7.18 (d, *J* 

= 8 Hz, 2H), 6.98 (d, J = 8 Hz, 2H), 4.68 (br s, 1H), 4.11 (q, J = 7.0 Hz, 2H), 3.46-3.42 (m, 1H), 3.10-2.96 (m, 2H), 2.76-2.69 (m, 1H), 2.03-1.97 (m, 3H), 1.65-1.62 (m, 2H), 1.24 (t, J = 7.0 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100.5 MHz) δ 170.9, 168.1, 167.2, 159.7, 150.7, 147.5, 139.7, 129.8, 120.8, 120.4 (q, <sup>1</sup>J<sub>CF</sub> = 257 Hz), 115.6, 44.7, 38.5, 36.3, 35.0, 32.2, 30.9, 14.8; <sup>19</sup>F NMR (CDCl<sub>3</sub>, 376.5 MHz) δ -57.9; HPLC (purity) 99.3%; HRMS Calcd. for C<sub>20</sub>H<sub>22</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub> (M+H)<sup>+</sup> 438.1748; Found 438.1734; Anal. Calcd. for C<sub>20</sub>H<sub>22</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>: C; 54.92, H; 5.07, N; 16.01. Found, C; 54.91, H; 5.01, N; 16.00.

Fig C.



To a microwave vial was added compound **1a** (200 mg, 0.46 mmol) in deuterated ethanol (CH<sub>3</sub>CH<sub>2</sub>OD, 4 mL). The solution was heated at 60 °C for 2 h under N<sub>2</sub> atmosphere. The solvent was removed under reduced pressure to provide crude **S10**. The residue was dissolved in deuterated ethanol (CH<sub>3</sub>CH<sub>2</sub>OD, 8 mL) and LiOtBu (25 mg, 0.31 mmol) was added. The resulting mixture was heated in a microwave reactor (200 W) at 120 °C for 2 h. The solvent was removed under reduced pressure to give a crude product, which was purified via silica gel column chromatography by eluting with EtOAc/hexane gradient to give **1e** as a white solid (150 mg, 74%). <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.11 (d, *J* = 8.6Hz, 2 H), 6.94 (d, *J* = 8.0 Hz, 2 H), 3.90 (s, 2 H), 3.37 (q, *J* = 7.2 Hz, 2 H), 2.95 (s, 2 H), 1.27 (t, *J* = 7.2 Hz, 3 H); <sup>13</sup>CNMR (100

MHz, CDCl<sub>3</sub>): 171.0, 166.4, 159.8, 147.5, 139.6, 133.0, 129.9, 121.1, 120.8, 119.1, 115.3, 41.9, 36.5, 34.6, 30.9, 29.8, 29.7, 14.5.  $m/z = 444.4 (M+H)^+$ . HRMS Calcd. for  $C_{20}H_{17}D_6F_3N_5O_3 (M+H)^+$  444.2124; Found 444.2117.

Fig D.



To a solution of N-Boc-piperid-4-one (**S1**) (1.5 kg, 7.5 mol) in THF (1 L) was added LiHMDS (7.5 L, 7.5 mol) dropwise at -78 °C under N<sub>2</sub> atmosphere, and the mixture was stirred for 1 h. Ethyl chlorooxalate (1.1 kg, 7.5 mol) was added at -78 °C, and stirring was continued for 5 h while allowing the cooling bath to warm to room temperature. Water (1 L) was added and the mixture was extracted with MTBE (2 x 1 L). The combined organic layers were washed (brine), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated under reduced pressure to give compound **S11** (1.5 kg, 67%) as a yellow oil.

To a solution of compound **S11** (500 g, 1.67 mol) in AcOH (1 L) was added urea (150 g, 2.51 mol) and the mixture was stirred at 50 °C for 18 h. The solvent was removed under reduced pressure and the residue was dissolved in dichloromethane (500 mL). The organic layer was washed with water (500 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to give a residue that was purified via silica gel chromatography eluting with dichloromethane/methanol (20:1) to give **S12** (150 g) as a black solid.

To a solution of compound **S12** (156 g, 0.48 mol) in dichloromethane (1.5 L) was added TFA (550 g, 4.8 mol) at room temperature, and the mixture was stirred for 18 h. The solvent was removed under reduced pressure to give 167 g of a residue that was used in the subsequent step without further purification. This material was dissolved in water (500 mL) and dioxane (500 mL). Benzyl chloroformate (127 g, 0.74 mol) and Na<sub>2</sub>CO<sub>3</sub> (106 g, 1.0 mol) were added and the mixture was stirred at room temperature for 18 h. Water (300 mL) was added and the mixture was extracted with dichloromethane (2 x 500 mL). The combined organic layers were washed (brine), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to give a residue that was purified via silica gel column chromatography eluting with dichloromethane/methanol (20:1) to give **S13** as a black solid.

To a solution of **S13** (45 g, 126 mmol) in acetonitrile (500 mL) was added POCl<sub>3</sub> (45 mL, 491 mmol) and the mixture was heated under reflux for 2 h. The solvent was removed under reduced pressure and the residue was purified via silica gel column chromatography, eluting with petroleum ether/ethyl acetate (3:1) to give **S14** (22.7 g, 50%) as a yellow solid. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.37-7.31 (m, 5 H), 5.18 (s, 2 H), 4.96 (s, 2 H), 4.46 (q, *J* = 7.2 Hz, 2 H), 3.84 (t, *J* = 6.0 Hz, 2 H), 3.06 (br s, 2 H), 1.41 (t, *J* = 7.2 Hz, 3 H); m/z = 376.0 (M+H)<sup>+</sup>.

A solution of compound **S14** (15 g, 39 mmol) in 7 N ammonia in methanol (50 mL, 6 mol) was heated at 50 °C in a sealed bottle for 2.5 h. The mixture was cooled to room temperature, and filtered by washing with methanol (20 mL). The solid was dried in a vacuum oven to give 13 g (99%) of compound **S15** as a green solid. This material was used without further purification.

A mixture of compound **S15** (2 g, 5.7 mmol) and trifluoroacetic acid (20 mL) was stirred at 35 °C for 16 h. The solvent was removed under reduced pressure to give compound **S16** (2.0 g) as a brown oil, which was used without further purification.

To a solution of compound **S16** (920 mg, 4.3 mmol) in anhydrous dichloromethane (50 mL) was added 4-trifluoromethoxyhydrocinnamic acid (**S9**, 1010 mg, 4.3 mmol), diisopropylethylamine (1650 mg, 13 mmol) and HATU (1640 mg, 4.3 mmol), and the mixture was stirred at room temperature for 15 h. The solvent was removed under reduced pressure and the residue was purified via silica gel column chromatography, eluting with petroleum ether/ethyl acetate (1:1) to give compound **S17** (1250 mg, 67%) as a white solid. <sup>1</sup>HNMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  7.24 (d, *J* = 8.0 Hz, 1 H), 7.14 (d, *J* = 8.0 Hz, 1 H), 7.05 (d, *J* = 8.0 Hz, 1 H), 6.89 (d, *J* = 8.0 Hz, 1 H), 5.04 (s, 1 H), 4.92 (s, 1 H), 3.78-3.71 (m, 2 H), 2.87-2.81 (m, 4 H), 2.74-2.69 (m, 2 H); m/z = 428.8 (M+H)<sup>+</sup>.

#### Synthesis of Intermediate S18 used for 1b and 1d

Acetonitrile (450 mg, 10.7 mmol) was added to a solution of  $LiAlD_4$  (1 g, 23 mmol) in anhydrous THF (15 mL), and the mixture was stirred at room temperature for 2 h. Water (8 mL) was added followed by bubbling through a saturated solution of HCl in methanol at 0 °C. The mixture was concentrated under reduced pressure to give compound **S18** (70 mg) as a yellow solid. This material was used without further purification.

#### Synthesis of 1b

To a solution of compound **S17** (50 mg, 0.12 mmol) in DMF (2 mL) was added compound **S18** (30 mg, 0.36 mmol), CsF (50 mg, 0.33 mmol), and diisopropylethylamine (80 mg, 0.63 mmol), and the mixture was stirred at 80 °C for 18 h. The mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified via preparative HPLC to give compound **1b** (15 mg, 29%) as a white solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz)  $\delta$  7.34 (d, *J* = 8.4 Hz, 1 H), 7.24 (d, J = 8.4 Hz, 1 H), 7.17 (d, *J* = 8.4 Hz, 1 H), 7.02 (d, *J* = 8.4 Hz, 1 H), 4.96 (br s, 2 H), 3.82-3.72 (m, 2 H), 3.01-2.87 (m, 2 H), 2.83-2.69 (m, 4 H), 1.20 (s, 3 H); m/z = 440.1 (M+H)<sup>+</sup>. HRMS Calcd. for C<sub>20</sub>H<sub>21</sub>D<sub>2</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub> (M+H)<sup>+</sup> 440.1873; Found 440.1872.

### Synthesis of 1c

To a mixture of compound **S17** (50 mg, 23 mmol) in DMF (2 mL) was added K<sub>2</sub>CO<sub>3</sub> (50 mg, 36 mmol) and d<sub>5</sub>-ethylamine-1,1,2,2,2 (100 mg, 23 mmol), and the mixture was stirred at room temperature for 16 h. The mixture was filtered and the crude product was purified by preparative HPLC to give compound **1c** (8.7 mg, 15%) as a white solid. <sup>1</sup>HNMR (CD<sub>3</sub>OD, 400 MHz)  $\delta$  7.34 (d, *J* = 8 Hz, 1 H), 7.24 (d, *J* = 8 Hz, 1 H), 7.16 (d, *J* = 8 Hz, 1 H), 7.01 (d, *J* = 8 Hz, 1 H), 4.98-4.95 (m, 1 H), 3.80-3.75 (m, 2 H), 2.99-2.73 (m, 7 H). m/z = 443.1 (M+H)<sup>+</sup>.

Fig E.



To a solution of benzylamine (10 g, 93 mmol) in dichloromethane (100 mL) was added trifluoroacetic acid (10.5 g, 93 mmol) dropwise at room temperature and the mixture was stirred for 1 h. The solid was filtered to give 19 g of a white solid S19. To a portion of this solid (7 g,  $\sim$ 32 mmol) was added a 20% solution of CD<sub>2</sub>O (10 mL, 72 mmol) in D<sub>2</sub>O and the mixture was sonicated for 10 min, and stirred at room temperature for 1 h. Allyltrimethylsilane (5.5 mL, 34 mmol) was added and the mixture was stirred at 40 °C. After 18 h, it was cooled to room temperature and diluted with water (10 mL) and the pH was adjusted to > pH 9 (as indicated by pH paper) with K<sub>2</sub>CO<sub>3</sub>. The mixture was extracted with ethyl acetate (3 x 30 mL), the combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated under reduced pressure to give an oil purified by silica gel column chromatography eluting that was by with

dichloromethane/methanol (10:1) to give compound **S20** (3.5 g, 57%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.32-7.28 (m, 5 H), 3.77-3.75 (m, 1 H), 3.62-3.48 (m, 2 H), 2.03-1.92 (m, 2 H), 1.65-1.62 (m, 2 H); exchangeable hydroxy proton not visible.

To a solution of compound **S20** (2.7 g, 14 mmol) and Boc<sub>2</sub>O (3.6 g, 18 mmol) in methanol (30 mL) was added Pd(OH)<sub>2</sub> (0.65 g) and the mixture was hydrogenated in a Parr shaker at 55 psi for 24 h. The mixture was filtered through Celite<sup>®</sup> and the filtrate was concentrated under reduced pressure to give an oil that was purified via silica gel column chromatography eluting with dichloromethane/methanol (10:1) to give compound **S21** (2.2 g, 78%) as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  3.86-3.05 (m, 1 H), 1.85-1.81 (m, 2 H), 1.65-1.62 (m, 2 H), 1.45 (s, 9 H); exchangeable hydroxy proton not visible.

To a solution of oxalyl chloride (825 mg, 6.5 mmol) in dichloromethane (40 mL) was added DMSO (1 g, 12.9 mmol) at -78 °C, and the mixture was stirred for 1 h. Compound **S21** (1.0 g, 5.0 mmol) in dichloromethane (15 mL) was added at -78 °C and stirring was continued for 2 h. Triethylamine (3.0 g, 30 mmol) was added and the mixture was allowed to warm to room temperature while stirring for 30 min. The mixture was diluted with dichloromethane (20 mL) and washed with sat. aq. citric acid (40 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to give compound **S22** (1 g, >99%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  2.42 (s, 4 H), 1.48 (s, 9 H).

To a solution of compound **S22** (2.0 g, 9.8 mmol) in toluene (30 mL) was added morpholine (0.9 g, 10.8 mmol) and the flask was equipped with a Dean-Stark trap. The reaction mixture was heated under reflux for 18 h, whereupon it was cooled to room temperature and concentrated

under reduced pressure to give compound S23 (2.6 g) as a yellow liquid. This material was used without further purification.

To a solution of compound **S23** (~2.6 g, ~9.5 mmol) in dichloromethane (15 mL) was added triethylamine (1.2 g, 11.7 mmol) and ethyloxalyl chloride (1.5 g, 11.0 mmol) dropwise at 0 °C, and the mixture was stirred at room temperature for 18 h. The mixture was filtered and the filtrate was concentrated under reduced pressure to give compound **S24** (4.5 g) as a yellow oil. This material was used without further purification.

To a solution of compound **S24** (~4.5 g, ~ 12 mmol) in ethanol (20 mL) was added Smethylthiourea (2.3 g, 12 mmol) and triethylamine (4.9 g, 48 mmol) and the mixture was heated under reflux for 18 h. The mixture was allowed to cool to room temperature and filtered to give a solid. The solid was washed with dichloromethane (20 mL) and the filtrate was concentrated under reduced pressure to give compound **S25** (0.7 g) as a white solid.

To a solution of compound **S25** (~0.7 g, 1.96 mmol) in methanol (15 mL) was added a solution of 7 N ammonia in methanol (15 mL, 105 mmol), and the mixture was stirred in a sealed bottle at 40 °C for 18 h. The mixture was cooled to room temperature and the solvent was removed under reduced pressure to give compound **S26** (~0.6 g) as a white solid. This material was used without further purification. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  7.74 (br s, 1 H), 5.53 (br s, 1 H), 2.94 (s, 2 H), 2.54 (s, 3 H), 1.46 (s, 9 H).

To a solution of compound **S26** (~0.35 g, 1.06 mmol) in dichloromethane (7 mL) was added mchloroperbenzoic acid (0.47 g, 2.5 mmol) in portions at 0 °C, and the mixture was allowed to warm to room temperature while stirring for 2 h. The reaction mixture was poured into a separatory funnel and washed with sat. aq. Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (2 x 10 mL), sat. aq. K<sub>2</sub>CO<sub>3</sub> (2 x 10 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated under reduced pressure to give compound **S27** (~300 mg) as a white solid. This material was used without further purification. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  3.36 (s, 3 H), 3.16 (s, 2 H), 1.48 (s, 9 H).

To a solution of compound **S27** (~365 mg, ~1.0 mmol) in THF (5 mL) was added **S18** (d<sub>2</sub>ethylamine, 320 mg, 3.2 mmol), and the mixture was stirred at 80 °C for 18 h. The solvent was removed under reduced pressure and the residue was purified by a preparative TLC (petroleum ether/ethylacetate) to give compound **S28** (110 mg) as a colorless oil.

To a solution of compound **S28** (110 mg) in dichloromethane (5 mL) was added 4.0 M HCl in dioxane (5 mL) dropwise at 0 °C, and the mixture was stirred at room temperature for 2 h. The mixture was filtered to give a solid that was further dried in a vacuum oven to give compound **S29** (105 mg, >99%) as a yellow solid

To a solution of compound **S29** (100 mg, 0.4 mmol) in dichloromethane (5 mL) was added 4trifluoromethoxyhydrocinnamic acid (**S9**, 98 mg, 0.4 mmol), triethylamine (112 mg, 1.1 mmol) and HATU (174 mg, 0.5 mmol), and the mixture was stirred at room temperature for 15 h. The solvent was removed under reduced pressure and the residue was purified via preparative HPLC to give the compound **1d** (75 mg, 45%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  7.84 (br s, 1 H), 7.19 (d, *J* = 8.0 Hz, 2 H), 7.01 (d, *J* = 8.0 Hz, 2 H), 5.47 (br s, 1 H), 5.03 (br s, 1 H), 3.01-2.94 (m, 2 H), 2.77-2.67 (m, 4 H), 1.29 (s, 3 H); m/z = 444.1(M+H)<sup>+</sup>. Fig F.



To a microwave vial was added compound **1d** (100 mg, 0.22 mmol) in deuterated ethanol (CH<sub>3</sub>CH<sub>2</sub>OD, 2 mL). The solution was heated at 60 °C for 2 h under N<sub>2</sub> atmosphere. The solvent was removed under reduced pressure to provide crude **S30**. The residue was dissolved in deuterated ethanol (CH<sub>3</sub>CH<sub>2</sub>OD, 4 mL) and NaOtBu (5 mg, 0.05 mmol) was added. The resulting mixture was heated in a microwave reactor (200 W) at 105 °C for 2 h. The solvent was removed under reduced pressure to give a residue, to which was added additional portion of NaOtBu (5 mg, 0.05 mmol) and deuterated ethanol (CH<sub>3</sub>CH<sub>2</sub>OD, 2 mL). The resulting mixture was heated in a microwave reactor (200 W) at 105 °C for 2 h. The solvent was removed under reduced pressure to give a residue, to which was added additional portion of NaOtBu (5 mg, 0.05 mmol) and deuterated ethanol (CH<sub>3</sub>CH<sub>2</sub>OD, 2 mL). The resulting mixture was heated in a microwave (200 W) at 105 °C for 1.5 h. The solvent was removed under reduced pressure to give a crude product, which was purified via silica gel column chromatography eluting with EtOAc/hexane gradient to give **1f** as white solid (85 mg, 85%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.12 (d, *J* = 8.6 Hz, 2 H), 6.94 (d, *J* = 8.1 Hz, 2 H), 2.95 (s, 2 H), 1.27 (s, 3 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 170.9, 168.1, 167.3, 150.9, 147.5, 139.6, 129.9, 120.9, 120.5 (q, <sup>1</sup>J<sub>CF</sub> = 256 Hz) , 119.1, 115.4, 44.0 (m), 41.9, 35.8(m), 34.6 (m), 30.8, 29.8 (m), 14.5. m/z = 448.4 (M+H)<sup>+</sup>. HRMS Calcd. for C<sub>20</sub>H<sub>13</sub>D<sub>10</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub> (M+H)<sup>+</sup> 448.2375; Found 448.2367.

Summary of spectral data for deuterated triazole compounds (2a-d)

Fig G.



<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.51 (d, *J* = 8.4 Hz, 2 H), 7.44-7.40 (m, 1 H), 7.01 (dd, *J* = 8.2, 2.3 Hz, 1 H), 6.87-6.78 (m, 3 H), 6.68 (br s, 1 H), 3.82 (s, 3 H), 3.39 (s, 3 H), 2.03-2.00 (m, 1 H), 1.04-0.80 (m, 4 H); m/z 374.2 9 (M+1)<sup>+</sup>.

Fig H.



<sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 7.53 (d, J = 8.4 Hz, 2 H), 7.44 (t, J = 8.4 Hz, 1 H), 7.12 (d, J = 5.6 Hz, 1 H), 6.84-6.82 (m, 3 H), 6.71 (s, 1 H), 3.43 (s, 3 H), 2.05 (p, J = 7.6 Hz, 1 H), 1.07-0.75 (m, 4 H); <sup>13</sup>C NMR (CD<sub>3</sub>OD, 100.5 MHz) δ 162.2, 162.0, 151.3, 147.0, 138.4, 134.3, 131.8, 130.3, 127.5, 119.0, 116.9, 116.1, 111.9, 109.9, 37.6, 8.5, 7.1; signal for expected septet for CD<sub>3</sub>-

N at ~ 55 ppm not above baseline.  $m/z = 377.0 (M+H)^+$ .\_HRMS Calcd. for  $C_{21}H_{17}D_3N_5O_2$ (M+H)<sup>+</sup> 377.1800; Found 377.1798.

Fig I.



<sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz)  $\delta$  7.53 (d, *J* = 8.4 Hz, 2 H), 7.44 (t, *J* = 8.4 Hz, 1 H), 7.12 (dd, *J* = 8.4, 2.4 Hz, 1 H), 6.84-6.82 (m, 3 H), 6.71 (s, 1 H), 3.84 (s, 3 H), 2.05 (p, *J* = 7.6 Hz, 1 H), 1.20-0.85 (m, 4 H); <sup>13</sup>C NMR (CD<sub>3</sub>OD, 100.5 MHZ)  $\delta$  160.7, 160.4, 149.7, 145.5, 136.9, 132.8, 130.3, 128.8, 126.0, 117.4, 115.4, 114.6, 110.4, 108.4, 54.8, 7.0, 5.5; signal for expected septet for -OCD<sub>3</sub> at ~ 36 ppm not above baseline. m/z = 377.2 (M+H)<sup>+</sup>. HRMS Calcd. for C<sub>21</sub>H<sub>17</sub>D<sub>3</sub>N<sub>5</sub>O<sub>2</sub> (M+H)<sup>+</sup> 377.1800; Found 377.1798.

Fig J.



<sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  7.35 (d, *J* = 8.4 Hz, 2 H), 7.30 (t, *J* = 8.4 Hz, 1 H), 6.96 (dd, *J* = 8.4, 2.4 Hz, 1 H), 6.76 (d, *J* = 8.4 Hz, 1 H), 6.69-6.55 (m, 2 H), 1.99 (pentet, *J* = 7.6 Hz, 1 H), 1.05-0.95 (m, 4 H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100.5 MHz)  $\delta$  160.6, 160.4, 150.3, 145.5, 137.1, 132.8, 130.1, 128.2, 125.6, 117.6, 115.7, 114.7, 110.4, 108.1, 54.8 (septet, J = 22.7 Hz), 36.8 (partially resolved septet, J = 26.4 Hz), 8.0, 6.2. m/z = 380.3 (M+H)<sup>+</sup>. HRMS Calcd. for C<sub>21</sub>H<sub>14</sub>D<sub>6</sub>N<sub>5</sub>O<sub>2</sub> (M+H)<sup>+</sup> 380.1988; Found 380.1984.















Fig N.









Fig Q.

proton MeOD









Fig T.

proton CDC13



Fig U.



Fig V.

proton CDC13













Fig Z.

proton MeOD





Fig AA.









<sup>&</sup>lt;sup>1</sup> Piotrowski DW, Futatsugi K, Warmus JS, Orr STM, Freeman-Cook KD, Londregan AT, et al. Identification of Tetrahydropyrido[4,3-*d*]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists. ACS Med. Chem. Lett. 2013;4(1): 63–68.

<sup>2</sup> Futatsugi K, Bahnck KB, Brenner MB, Buxton J, Chin JE, Coffey SB, et al. Optimization of triazole-based TGR5 agonists towards orally available agents.

Med. Chem. Commun. 2013; 4: 205–210.